Researchers at the National Institutes of Health have identified why semaglutide, the active ingredient in Ozempic and Wegovy, loses effectiveness over time as patients hit weight-loss plateaus. The team discovered that the drug triggers distinct cellular responses in appetite-controlling neurons in the brain, explaining individual variation in drug response.
The NIH scientists found that semaglutide activates brain cells differently depending on their specific type and location. Some neurons respond robustly to the treatment while others show minimal activation. This heterogeneous response helps explain why patients experience plateaus after initial weight loss and why the drugs work better for some people than others.
The research offers a mechanistic explanation for a common clinical challenge. Many patients taking GLP-1 receptor agonists achieve significant weight loss in the first months but then experience a plateau where additional weight loss stalls despite continued treatment. Understanding why this happens at the cellular level opens new therapeutic avenues.
The team identified potential methods to extend the drugs' weight-loss effects by targeting the less-responsive neurons. By modulating these cells, researchers believe they could help patients overcome plateaus and achieve sustained weight loss. The approach suggests combination therapies or dose adjustments tailored to individual brain cell responses could enhance long-term outcomes.
The findings underscore that semaglutide's mechanism is more complex than a simple on-off switch in appetite centers. Rather, the drug creates a nuanced pattern of neural activation that varies across brain regions. This complexity explains why one-size-fits-all dosing fails for many patients and why personalized approaches may prove more effective.
The research has implications beyond weight loss. Understanding how GLP-1 drugs interact with appetite-controlling circuits could inform treatment of obesity-related metabolic disorders and potentially guide development of next-generation therapies with fewer plateaus. Further research will test whether interventions targeting underactive neurons